MedPath

Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors

Completed
Conditions
Liver Failure
Registration Number
NCT05958420
Lead Sponsor
Akdeniz University
Brief Summary

This study aimed to determine high-density lipoprotein (HDL) subfraction profile and HDL-associated enzyme changes in liver failure patients and healthy donors.

Detailed Description

Objectives: This study aimed to determine high-density lipoprotein (HDL) subfraction profile and HDL-associated enzyme changes in liver failure patients and healthy donors.

Materials and Methods: Twenty liver failure patients and twenty healthy donors are selected. Blood samples obtained from all patients prior to transplant will analyzed. HDL subfraction analysis will done by continuous disc polyacrylamide gel electrophoresis. Plasma levels of apolipoprotein A-1 (ApoA-I), cholesteryl ester transfer protein (CETP), and lecithin-cholesterol acyltransferase (LCAT) will determined by enzyme-linked immunosorbent assay.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Liver failure patients
Exclusion Criteria
  • patients not giving consent
  • Participants who had oncological and hematological diseases, coronary failure, kidney failure, malnutrition, diabetes, traumatic brain injury, or cadaveric LT and who were using psychoactive medicines or having a respiratory system or CNS diseases were excluded from the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
HDL SubfractionsBlood will collected from all patients before surgery

Evaluation of HDL Subfractions in groups

Secondary Outcome Measures
NameTimeMethod
HDL-associated enzymesBlood will collected from all patients before surgery

ApoA1, CETP and LCAT levels in groups

Trial Locations

Locations (1)

AkdenizU

🇹🇷

Antalya, Turkey

© Copyright 2025. All Rights Reserved by MedPath